Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share from the same period last year. The company reported $25.000 thousand in sales this quarter.